Literature DB >> 8488939

Extending the limits of lung cancer resection.

R W Aye1, T P Mate, H N Anderson, L P Johnson, L Hill.   

Abstract

Patients with locally advanced bronchogenic carcinoma are often considered to have unresectable disease because of invasion into vital structures, or they undergo resection with questionable or involved margins, which results in local recurrence later. Brachytherapy (direct application of radioactive sources to the tumor bed) offers the potential to provide tumoricidal doses of radiation to the target area with minimal toxicity to surrounding structures. In this study, one of two different techniques of brachytherapy was utilized to treat 15 highly selected patients with histologically positive (n = 8) or suspicious (n = 7) margins after resection. The techniques were easy to apply and were not associated with any complications directly related to their use. One postoperative death resulted from a perforated peptic ulcer. In the remaining 14 patients, at a mean follow-up of 38 months, local control was complete in 12 (86%) patients, and 8 patients are alive, with 7 free of disease. Thoracic brachytherapy may offer the potential for cure to patients whose disease would otherwise be considered inoperable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8488939     DOI: 10.1016/s0002-9610(05)80437-4

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  High- and low-dose-rate intraoperative radiotherapy for thoracic malignancies resected with close or positive margins.

Authors:  Christopher Fleming; Andreas Rimner; Gil'ad N Cohen; Kaitlin M Woo; Zhigang Zhang; Kenneth E Rosenzweig; Kaled M Alektiar; Michael J Zelefsky; Manjit S Bains; Abraham J Wu
Journal:  Brachytherapy       Date:  2016-01-26       Impact factor: 2.362

2.  Effectiveness of 125I seed implantation in the treatment of non-small cell lung cancer during R2 resection.

Authors:  Wei Li; Yifeng Zheng; Yunming Li; Jing Guan; Jianqing Jiang; Yongkang Yu; Xiushan Zheng; Lie Yang
Journal:  Oncol Lett       Date:  2017-09-21       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.